Acurx Pharmaceuticals Reports Q3 2026 Financial Results and Initiates PATHFINDER Trial Enrollment
Acurx Pharmaceuticals (ACXP) reported its third-quarter 2026 financial results, highlighting a net loss of $2.6 million ($0.49 per diluted share). The company strengthened its liquidity position with a cash balance of $9.7 million as of September 30, 2026, up from $7.6 million at the end of 2025. This capital includes $1.5 million raised through an equity line of credit during the quarter. On the clinical front, Acurx has officially commenced enrollment for its PATHFINDER trial, a 20-patient study targeting recurrent Clostridium difficile infection (CDI). Management expects current funding to provide a 12-month runway, which is sufficient to complete the PATHFINDER trial by Q3 2027. The company is also evaluating regulatory strategies for ibezopolstat, including potential filing via the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).
Tickers: $ACXP
Topics: cash runway clinical trials earnings report financial results
Read the full article at Motley Fool
Part of the story Acurx Pharmaceuticals Reports Q3 2026 Financial Results and Initiates PATHFINDER Trial Enrollment (6 articles)